Market Wire - Evaluation of the Cost-Effectiveness of Sibutramine (Meridia) Within a Managed Care Weight-Loss Program; 33% More Drug Formulary Switches Result From Letter…
The July-August 2005 issue of the Journal of
Managed Care Pharmacy (JMCP) is now available in print and online.
Featured articles include:
Cost-Effectiveness of Sibutramine (Meridia) Within a Managed Care
Weight-Loss Program …
Pharmacoeconomic evaluation of the results from a prospective randomized
trial found that adding sibutramine to a comprehensive weight management
behavioral modification program increased the total cost by $44 per
additional pound of weight loss. The change in total health care cost at 12
months was a median $1,279 increase in the sibutramine group compared with
$271 increase for the nondrug group (P < 0.001), and the change in
obesity-related total cost was a median $408 increase in the sibutramine
group compared with a $31 increase for the nondrug group (P < 0.001).
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
An accompanying editorial, “‘U Can’t Touch This’ with Pharmacotherapy Alone
for Weight Loss or Smoking Cessation” suggests that the pharmacoeconomic
benefits may be established for tobacco cessation but are less clear for
weight-loss medications. The average weight loss at 12 months in the
managed care clinical study was 5.0 pounds (2.2% of baseline body weight)
for the behavioral weight management program compared with 13.7 pounds
(4.8% of baseline body weight) for the sibutramine behavioral weight
management program. This absolute difference of less than 3% of baseline
body weight loss with sibutramine, combined with the absence of benefits in
measures of cholesterol, glucose, or hemoglobin A1c in patients with
diabetes, argues against population-based coverage of weight-loss
medications at this time.
Randomized Controlled Trial Finds 33% More Drug Formulary Switches for
Patient-Specific Letter Intervention Program …
A randomized controlled trial found that beneficiaries who received a
targeted, patient-specific letter regarding an impending change in drug
formulary status and copayment amount were 1.33 times more likely to switch
to a formulary drug (P < 0.001). Prior to adjustment for baseline
differences, the absolute rate of change to a preferred formulary drug was
19.2% in the letter-intervention arm versus 12.0% in the control arm (P <
0.001).
The Journal of Managed Care Pharmacy is published nine times per year and
is a benefit of membership in the Academy of Managed Care Pharmacy. A
peer-reviewed publication of original research for pharmacy practitioners
and health care providers, JMCP is approved by the National Library of
Medicine and indexed in MEDLINE/PubMed. The current edition is available
at: http://www.amcp.org/data/jmcp/July2005.pdf.
Questions about the publication may be directed to Editor-in-Chief Frederic
R. Curtiss, PhD, RPh, CEBS, at fcurtiss@amcp.org.
The Academy of Managed Care Pharmacy’s mission is to empower its members to
serve society by using sound medication management principles and
strategies to achieve positive patient outcomes. AMCP has more than 4,800
members nationally who provide comprehensive coverage and services to the
more than 200 million Americans served by managed care. More news and
information about AMCP can be obtained on its website, www.amcp.org.
Contact:
Carolyn Stables
703-683-8416 ext 308
Email Contact
